CARsgen Therapeutics Announces 2026 Interim Results

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results. Cash and cash equivalents were around RMB1,400 million as of June 30, 2026. Cash and cash equivalents at the end of 2026 are expected to be not less than RMB1,200 million. In light of operational factors, we expect to have adequate cash into 2030. During H1, 2026, CARsgen has received a total of 110 confirmed orders of zevor-cel from its commercialization partner Huadong Medicine. Satri-cel receives NMPA approval in June 2026 as world's first and only CAR-T for solid tumors. Data of satri-cel as sequential therapy after 1L treatment in patients with G/GEJA have been presented at the 2026 ASCO Annual Meeting. Multiple allogeneic CAR T-cell products are under development based on the proprietary THANK‑u Plus ® platform. Among them, research results for CT0596 in the treatment of R/R MM and PCL, as well as for CT1190B in the treatment of R/R B‑NHL, have been presented at the EHA2026 Congress. In August 2026, both products successively received IND approvals from the NMPA. In vivo CAR T-cell products are under development based on the proprietary CARvivo™ platform. An IIT of KJ‑C2529, which targets CD19/CD20 for the treatment of B‑cell malignancies, has been initiated. In the first half of 2026, CARsgen achieved a historic breakthrough—satri-cel became the world's first approved CAR‑T product for solid tumors. This milestone not only validates our decade‑long dedication and persistence in the solid tumor field, but also underscores our leading position in the global CAR T-cell therapy landscape. Meanwhile, the commercialization of zevor-cel is progressing steadily, with continuous improvements to the diversified payment system and increasing product accessibility. The Company maintains a sound financial position, and our ample cash reserves provide a solid foundation for our ongoing global expansion, advancement into earlier lines of treatment, and development of next‑generation allogeneic/ in vivo CAR‑T technologies. CARsgen's revenue was around RMB62 million for the six months ended June 30, 2026 mainly from zevorcabtagene autoleucel (an autologous BCMA CAR T-cell product), in which the primary revenue of zevorcabtagene autoleucel was calculated on the basis of ex-works price, rather than on the basis of end-of-market prices. Our revenue is recognized upon completion of ex-works delivery of products. Due to the inherent time cycle of CAR-T manufacturing, there is a discrepancy between the number of orders obtained from Huadong Medicine and number of ex-works deliveries. CARsgen's gross profit was around RMB42 million for the six months ended June 30, 2026. In the commercialization stage, we are demonstrating a strong cost competitive advantage, which is mainly due to self-manufacture for plasmids and vectors with stable output and high yield per batch. Cash and cash equivalents were around RMB1,400 million as of June 30, 2026. Cash and cash equivalents at the end of 2026 are expected to be not less than RMB1,200 million. In light of operational factors, we expect to have adequate cash into 2030. Zevorcabtagene autoleucel (zevor-cel, R&D code: CT053) is an autologous fully human CAR T-cell product against B-cell maturation antigen (BCMA) approved by the National Medical Products Administration (NMPA.